Navigation Links
FDA Advisory Committee Unanimously Recommends Approval of Ustekinumab for Treatment of Moderate to Severe Plaque Psoriasis
Date:6/17/2008

HORSHAM, Pa., June 17 /PRNewswire/ -- Centocor, Inc. announced today that the Dermatologic and Ophthalmic Drugs Advisory Committee (DODAC) of the U.S. Food and Drug Administration (FDA) has unanimously recommended the approval of ustekinumab, a new subcutaneous, investigational biologic therapy for the treatment of adult patients with moderate to severe plaque psoriasis. Ustekinumab is a new human monoclonal antibody with a novel mechanism of action that targets the cytokines interleukin-12 (IL-12) and interleukin-23 (IL-23), naturally occurring proteins that are important in the body's regulation of immune responses and that are also believed to play an important role in psoriasis.

"We are very pleased with the advisory committee's support for the approval of ustekinumab," stated Jerome A. Boscia, M.D., Senior Vice President, Clinical, Centocor R&D. "For many patients, psoriasis is a serious disease, and they are in need of additional treatment options. It is our hope that the FDA will consider this recommendation and, upon completion of its review process, make ustekinumab available to patients with moderate to severe psoriasis."

The committee reviewed data from one of the largest biologic clinical programs in psoriasis, which included two large Phase 3 multicenter, randomized, double-blind, placebo-controlled trials evaluating the safety and efficacy of ustekinumab involving more than 2,000 patients. Results of these Phase 3 trials were recently published in The Lancet, which showed that a majority of patients treated with ustekinumab experienced significant skin clearance by week 12 and sustained efficacy through at least week 76 with ustekinumab maintenance therapy every 12 weeks. In December 2007, Centocor announced that a Biologics License Application had been submitted to the FDA.

DODAC is convened on request of the FDA to review and evaluate safety and efficacy data of human drug products for use in the treatment of dermatologic
'/>"/>

SOURCE Centocor, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. UBC Forms European Advisory Board to Enhance Data Quality of CNS Trials
2. Ortho Biotech Statement on U.S. Food and Drug Administration Oncologic Drugs Advisory Committee Vote
3. FDA Advisory Committee Unanimously Recommends U.S. Approval of Sugammadex, the First and Only Selective Relaxant Binding Agent
4. HUYA Bioscience Intl Announces World-Class Clinical Advisory Team for New Anti-Arrhythmic Compound Sourced From China
5. FDA Advisory Committee Supports Efficacy and Safety of Zyprexa(R) Long-Acting Injection (LAI) for Schizophrenia Treatment
6. Solvay Pharmaceuticals, Inc. Responds to Advisory Committee Recommendation for Further Study of Tedisamil to Treat Atrial Fibrillation
7. Schiffrin Barroway Topaz & Kessler, LLP and Janet Jenner & Suggs, LLC Comment on Conagra Advisory Regarding Pot Pies Linked to Salmonella Outbreak
8. Targeted Genetics Reports on Recombinant DNA Advisory Committee (RAC) Review of its Phase 1/2 Trial of tgAAC94 for Rheumatoid Arthritis
9. Statement by KCP Chairman Dr. Edward Jones in Response to FDA Advisory Committee on Benefits and Risks of Erythropoietin-Stimulating Agents in Treatment of Kidney Patients
10. FDA Advisory Committees Recommend Continued U.S. Marketing Authorization for Trasylol(R)
11. IDM Pharma Announces Non-Binding Opinion of the European Committee for Medicinal Products for Human Use (CHMP) that Mifamurtide (L-MTP-PE) Provides a Possible Clinical Benefit in Survival
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)...  Research and Markets ( http://www.researchandmarkets.com/research/6k27gw/dental ) has announced the ... Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 ... (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) ... in order to treat dental impairments, for tooth restoration ...
(Date:1/15/2014)... Jan. 15, 2014  Celsion Corporation (the "Company") (NASDAQ: ... from institutional investors to purchase an aggregate of approximately ... at-the-market registered direct offering, led by a dedicated health ... purchase agreements with these investors pursuant to which the ...
(Date:1/15/2014)... 2014 BreedIT Corp (OTC: BRDT), through ... of highly sophisticated agro-breeding solutions for plant breeders and ... Company,s board of directors appointed chemistry and pharmaceutical industry ... member of the board. From 1975 to ...
Breaking Medicine Technology:Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 2Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 3Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3
... Academy of Managed Care Pharmacy (AMCP) is pleased to ... Pharmacy Claims – a resource that fulfills a ... challenge between the community and managed care pharmacy practice. ... The 21-page Model Guidelines document ...
... today that it has completed notifying customers of a ... the United States and has confirmed that 51 have ... on October 11, 2011 to address a manufacturing issue ... reports of ventilator malfunctions, failures or injuries related to ...
Cached Medicine Technology:Academy of Managed Care Pharmacy (AMCP) Releases Model Audit Guidelines for Pharmacy Claims 2Academy of Managed Care Pharmacy (AMCP) Releases Model Audit Guidelines for Pharmacy Claims 3Respironics, Inc. Completes Voluntary Recall Notification of a Limited Number of Trilogy 100 Ventilators 2
(Date:4/17/2014)... military personnel who served in Iraq and Afghanistan ... injury (TBI) were compared to military personnel without ... Differences in measures of overall disability, cognitive function, ... are reported in an article in Journal ... Ann Liebert, Inc., publishers. The article is available ...
(Date:4/17/2014)... NY (April 16, 2014) The cause of neuronal ... new study proposes that neurons may be mistaken for ... system, similar to the way autoimmune diseases like type ... body,s cells. The study was published April 16, 2014, ... new, and likely controversial, idea in Parkinson,s disease; but ...
(Date:4/17/2014)... BostonResearchers from Boston University School of Medicine (BUSM) ... alcohol consumption in an experimental model. The findings, ... and Alcohol Abuse , may lead to more ... alcohol is one of the leading causes of ... significant negative economic impact by limiting the productivity ...
(Date:4/17/2014)... off depression among retirees, particularly among those who live ... The Journals of Gerontology, Series B: Psychological Sciences and ... Use and Depression Among Retired Older Adults in the ... that Internet use reduced the probability of a depressed ... , Late-life depression affects between 5 and 10 million ...
(Date:4/17/2014)... ribbon representing a disease. A pink ribbon is well known ... think of with lung cancer?, Although white has been identified ... black may be the only one they think fits., A ... smokers between the ages of 51 to 79 years old, ... these patients, the emotional toll it can have and how ...
Breaking Medicine News(10 mins):Health News:Long-term effects of battle-related 'blast plus impact' concussive TBI in US military 2Health News:Is Parkinson's an autoimmune disease? 2Health News:BUSM researchers find anti-seizure drug may reduce alcohol consumption 2Health News:Internet use may cut retirees' depression 2Health News:Unraveling the 'black ribbon' around lung cancer 2
... another drawback for sedated patients, study finds , FRIDAY, ... intensive care who aren,t sedated require fewer days on ... care unit than those who are sedated, new research ... adult patients expected to need mechanical ventilation for more ...
... a biomarker that could help doctors select patients with ... such as Enbrel, a tumor necrosis factor (TNF)-antagonist drug. ... Surgery in collaboration with rheumatologists at University of Southern ... Arthritis & Rheumatism. "While our study was performed ...
... ... announced that its non-profit organization, PrideAmerica is teaming up with the Starkey Hearing Foundation ... 3rd, from noon – 4 pm at the Eden Roc Renaissance Hotel in Miami ... Westlake ...
... , DETROIT , Jan. 29 After ... has been named the new president and chief executive officer ... Dr. Bepler will begin his new position Feb. 1, ... In addition to his chief administrative duties, Dr. Bepler will ...
... study authors suggest , FRIDAY, Jan. 29 (HealthDay News) -- ... they think the faces are odd-shaped flowers, a new study ... and France determined that bees could be trained to recognize ... for doing so. , However, this doesn,t mean that bees ...
... Non-Profit ... Agency for Website Support , ... St. Louis, MO (PRWEB) January 29, 2010 -- The Net Impact , a St. ... Foundation (KSF), an organization focused on working to provide support to family and friends of ...
Cached Medicine News:Health News:Sedation Linked to Longer Stay in ICU 2Health News:Biomarker could help doctors tailor treatment for rheumatoid arthritis 2Health News:Biomarker could help doctors tailor treatment for rheumatoid arthritis 3Health News:CallSource joins Starkey Hearing Foundation to Tackle Children's Hearing Loss in Super Bowl Mission 2Health News:Karmanos Cancer Institute in Detroit Names Gerold Bepler, M.D., Ph.D., as CEO 2Health News:Karmanos Cancer Institute in Detroit Names Gerold Bepler, M.D., Ph.D., as CEO 3Health News:Karmanos Cancer Institute in Detroit Names Gerold Bepler, M.D., Ph.D., as CEO 4Health News:The Net Impact is Proud to Announce Partnership with the Karla Smith Foundation 2Health News:The Net Impact is Proud to Announce Partnership with the Karla Smith Foundation 3Health News:The Net Impact is Proud to Announce Partnership with the Karla Smith Foundation 4
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: